BACKGROUND: Obesity and type 2 diabetes are increasing significantly in the Hispanic population and in the Hispanic population with schizophrenia. In the Diabetes Prevention Project (DPP), cognitive—behavioral (CB) interventions were more effective in reducing weight and preventing diabetes.OBJECTIVE: To test a CB group intervention based on the DPP model among Hispanic individuals with schizophrenia on weight, body mass index (BMI), and waist—hip circumference (WH).STUDY DESIGN:Pilot study using a pre—post quasi-experimental design and convenience sample of 8 subjects from a public mental health clinic who met for 8 weekly group meetings.RESULTS:No significant differences in BMI, weight, or WH scores based on t-test results; the subjects' weight remained stable, there was a trend toward weight loss, and no one gained weight during the trial. CONCLUSIONS:No further weight gain is a finding that merits further research using a larger sample size and a randomized controlled design. J Am Psychiatr Nurses Assoc, 2008; 13(6), 353-359.
Allison, D. , & Casey, D. (2001). Antipsychotic-induced weight gain: A review of the literature. Journal ofClinical Psychiatry, 62 (suppl. 7), 22-31 .
2.
Allison, D. , Fontaine, K. , Heo, M. , Mentore, J. , Cappelleri, J. , Chandler, L. , et al. (1999). The distribution of body mass index among individuals with and without schizophrenia . Journal of Clinical Psychiatry, 60, 215-220 .
3.
Allison, D.B. , Mentore, J.L. , Heo, M. , Chandler, L.P. , Cappelleri, J.C. , Infante, M.C. , et al. (1999). Antipsychotic induced weight gain: A comprehensive research synthesis . American Journal of Psychiatry, 156, 1686-1696 .
4.
Ayllon, T. (1963). Intensive treatment of psychotic behaviour by stimulus satiation and food reinforcement . Behaviour Research and Therapy, 1 (1), 53-61 .
5.
Bandura, A. (1977). Self-efficacy: Toward a unifying theory of behavioral change . Psychological Review, 84, 191-215 .
6.
Bandura, A. (1997). Self-efficacy: The exercise of control. New York: W. H. Freeman and Company .
7.
Brown, S. , Birtwistle, J. , Roe, L. , & Thompson, C. (1999). The unhealthy lifestyle of people with schizophrenia . Psychological Medicine, 29 (3), 697-701 .
8.
Casey, D. , Haupt, D. , Newcomer, J. , Henderson, D. , Sernyak, M.J. , Davidson, M. , et al. (2004). Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. Journal ofClinical Psychiatry, 65 (suppl. 7), 4-18 .
9.
Centorrino, F. , Wurtman, J. , Duca, K. , Fellman, V. , Fogarty, K. , Berry, J. , et al. (2006). Weight loss in overweight patients maintained on atypical antipsychotic agents . International Journal of Obesity, 30, 1011-1016 .
10.
Cooper, Z. , & Fairburn, C. (2001). A new cognitive behavioural approach to the treatment of obesity . Behaviour Research and Therapy, 39, 499-511 .
11.
Faulkner, G. , Cohn, T. , & Remington, G. (2007). Interventions to reduce weight gain in schizophrenia . Cochrane Database of Systematic Reviews, Issue 1, Art. No.: CD005148.
12.
Ford, E.S. , Giles, W.H. , & Dietz, W.H. (2002). Prevalence of the metabolic syndrome among US adults. Journal of theAmerican Medical Association, 287 (3), 356-359 .
13.
Green, A.I. , Patel, J.K. , Goisman, R.M. , Allison, D.B. , & Blackburn, G. (2000). Weight gain from novel antipsychotic drugs: Need for action. General HospitalPsychiatry, 22 (4), 224-235 .
14.
Henderson, D.C. (2002). Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents . Current Diabetes Reports, 2 (2), 135-140 .
15.
Henderson, D.C. , Cagliero, E. , Copeland, P.M. , Borba, C.P. , Evins, E. , Hayden, D. , et al. (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequent sampled intravenous glucose tolerance test and minimal model analysis . Archives of General Psychiatry, 62, 19-28 .
16.
Henderson, D. , Nguyen, D. , Copeland, P. , Hayden, D. , Borba, C. , Louie, P. , et al. (2005). Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study . Journal of Clinical Psychiatry, 66, 1116-1121 .
17.
Kato, M.M. , Currier, M.B. , Gomez, C.M. , Hall, L. , & Gonzalez-Blanco, M. (2004). Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. The Primary Care Companion to the Journal ofClinical Psychiatry, 6 (2), 74-77 .
18.
Knowler, W.C. , Barrett-Connor, E. , Fowler, S.E. , Hamman, R.F. , Lachin, J.M. , Walker, E.A. , et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . The New England Journal of Medicine, 346 (6), 393-403 .
19.
Lean, M. , & Pajonk, F. (2003). Patients on atypical antipsychotics: Another high-risk group for diabetes . Diabetes Care, 26, 1597-1605 .
20.
Lieberman, J.A. (2004). Metabolic changes associated with antipsychotic use. Primary Care Companion, Journal ofClinical Psychiatry , 6 (suppl. 2), 8-13 .
21.
Lindenmayer, J. , Czobor, P. , Volavka, J. , Citrome, L. , Sheitman, B. , McEvoy, J.P. , et al. (2003). Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics . American Journal of Psychiatry, 160 (2), 290-296 .
22.
Nawaz, H. , & Katz, D. (2001). American College of Preventive Medicine Practice Policy Statement: Weight management counseling of overweight adults . American Journal of Preventive Medicine, 21, 73-78 .
Newcomber, J. (2006). Medical risk in patients with bipolar disorder and schizophrenia. Journal ofClinical Psychiatry, 67, e16 .
25.
Schwartz, T.L. , Nihalani, N. , Virk, S. , Jindal, S. , & Chilton, M. (2004). Psychiatric medication-induced obesity: Treatment options . Obesity Reviews, 5 (4), 233-238 .
26.
Shah, M. , Coyle, Y. , Kavanaugh, A. , Adams-Huet, B. , & Lipsky, P.E. (2000). Development and initial evaluation of a culturally sensitive cholesterol-lowering diet program for Mexican and African American patients with systemic lupus erythematous . Arthritis Care and Research, 13 (4), 205-212 .
27.
Smith, S.C. , Clark, L.T. , Cooper, R.S. , Daniels, S.R. , Kumanyika, S.K. , Ofili, E. , et al. (2005). Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: Report of the obesity, metabolic syndrome, and hypertension writing group . Circulation, 111(10), 134-139 .
28.
Thakore, J.H. , Mann, J.N. , Vlahos, I. , Martin, A. , & Reznek, R. (2002). Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia . International Journal of Obesity, 26 (1), 137-141 .
29.
Toalson, P. , Ahmed, S. , Hardy, T. , & Kabinoff, G. (2004). The metabolic syndrome in patients with severe mental illnesses. The Primary Care Companion to the Journal ofClinical Psychiatry, 6 (4), 152-158 .
30.
Umbricht, D. , Flury, H. , & Bridler, R. (2001). Cognitive behavior therapy for weight gain [Letter to the Editor] . American Journal of Psychiatry,158, 971 .
31.
Wadden, T.A. , Berkowitz, R.I. , Sarwer, D.B. , Prus-Wisniewski, R. , & Steinberg, C. (2001). Benefits of lifestyle modification in the pharmacological treatment of obesity. Archives ofInternal Medicine, 161 (2), 218-227 .
32.
Weber, M. , & Wyne, K. (2006). A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics . Schizophrenia Research, 83, 95-101 .
33.
Williamson, D.A. , & Perrin, L.A. (1996). Behavioral therapy for obesity . Endocrinology and Metabolism Clinics of North America, 25 (4), 943-954 .
34.
Wing, R. , & Gillis, B. (1996). The diabetes prevention program's lifestyle change program. Section 7: Guidelines for implementing the DPP lifestyle intervention . Pittsburgh, PA: University of Pittsburgh . Retrieved August 13, 2007, from http://www.bsc.gwu.edu/dpp/manuals.htmlvdoc
